Clinical trials: Cerebral Infarction
Cerebral Ischemia, Cardiac Arrest
Neuroprotective Goal Directed Hemodynamic Optimization in Post-cardiac Arrest Patients
The primary objective of the Neuroprotect trial is to assess whether or not a new goal directed hemodynamic optimization strategy can reduce cerebral ischemia in post-cardiac arrest (CA) patients.
- Trial name
- NEUROPROTECT (NCT02541591)
- Testing
- Neuroprotective goal directed hemodynamic optimization, MAP > 65mmHg
- Where
- 2 sites in Belgium
- Volunteers
- 112 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Chronic Cerebral Ischemia
Study on Efficacy and Safety of Divaza in Patients With Chronic Cerebral Ischemia and Cognitive Disorders
An open-label, prospective, observational, multicenter study. The study enrolls adult outpatients with CCI from 8 federal districts of the Russian Federation.
- Trial name
- DIAMANT (NCT04370028)
- Testing
- Divaza
- Volunteers
- 2,583 people
- Sponsor
- Materia Medica Holding
Ischemic Symptoms, Cerebral Infarction
Pletaal SR Post Marketing Observational Study
This is a Post Marketing Observational Study of cilostazol (Pletaal® SR capsule). As this study is observational in nature to collect the safety data after administrating the Pletaal SR capsule, from baseline to 16 weeks.
- Trial name
- PLTSRPMOS (NCT01782833)
- Testing
- This is Non-interventional study
- Where
- 4 sites in South Korea
- Volunteers
- 3,635 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Type 2 Diabetes Mellitus
Pioglitazone Tablets Specified Drug-use Survey <Survey on Glycemic Control in Type 2 Diabetic Patients With a History of Cerebral Infarction>
The purpose of this survey is to evaluate the effects on glycemic control and to evaluate the safety of long-term use of pioglitazone tablets (Actos Tablets) in type 2 diabetic patients with inadequate glycemic control and a…
- Trial name
- NCT02181842
- Testing
- Pioglitazone
- Volunteers
- 246 people
- Sponsor
- Takeda
Sickle Cell Anemia, Stroke
Silent Cerebral Infarct Transfusion Multi-Center Clinical Trial
The goal of this study is to determine the effectiveness of blood transfusion therapy for prevention of silent cerebral infarct (stroke) in children with sickle cell anemia.
- Trial name
- SIT (NCT00072761)
- Testing
- transfusion therapy
- Where
- United States
- Volunteers
- 196 people
- Sponsor
- Washington University School of Medicine
Cardiovascular Disease
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
This study evaluates the PCSK9 inhibitor, Bococizumab (PF-04950615;RN316), compared to placebo, in reducing the occurrence of major cardiovascular events, including cardiovascular death, myocardial infarction, stroke, and…
- Trial name
- SPIRE-1 (NCT01975376)
- Testing
- bococizumab (PF-04950615)
- Where
- 1,745 sites in United States, Argentina and 34 more
- Volunteers
- 16,784 people
- Sponsor
- Pfizer
Brain Edema, Stroke, Acute
Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction
The primary objective of Part 1 of the study is to determine if BIIB093 improves functional outcome at Day 90 as measured by the modified Rankin Scale (mRS) when compared with placebo in participants with Large Hemispheric…
- Trial name
- CHARM (NCT02864953)
- Testing
- BIIB093
- Where
- 250 sites in United States, Australia and 22 more
- Volunteers
- 535 people
- Sponsor
- Remedy Pharmaceuticals, Inc.
Chronic Cerebral Ischemia
Safety and Efficacy of Sequential Therapy With Mexidol® in Patients With Chronic Cerebral Ischemia
The purpose of this study is to evaluate safety and efficacy of sequential treatment with Mexidol® in patients with chronic cerebral ischemia (CCI).
- Trial name
- MEMO (NCT06834490)
- Testing
- Mexidol
- Where
- 14 sites in Russia, Uzbekistan
- Volunteers
- 318 people
- Sponsor
- Pharmasoft
Atrial Fibrillation
Trial of Apixaban vs Warfarin in Reducing Rate of Cognitive Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Patients With Atrial Fibrillation
The investigators' central hypothesis is that in patients with atrial fibrillation, anticoagulation with Apixaban reduces the rate of decline in cognitive function, when compared to Warfarin.
- Trial name
- ARISTA (NCT03839355)
- Testing
- Apixaban, Warfarin
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Mayo Clinic
Stroke, Brain Infarction
Arm Rehabilitation Study After Stroke
This study is about arm and hand recovery after a stroke. The investigators are testing an experimental arm therapy called Accelerated Skill Acquisition Program (ASAP) which combines challenging, intensive and meaningful practice…
- Conditions
- Stroke, Brain Infarction, Brain Ischemia, Cerebral Infarction
- Trial name
- ICARE (NCT00871715)
- Testing
- Accelerated Skill Acquisition Program (ASAP), Dose-Equivalent Usual & Customary Care - DEUCC, Usual and Customary Care - UCC
- Where
- 8 sites in United States
- Volunteers
- 361 people
- Sponsor
- University of Southern California
Stroke, Acute
The Intravascular Cooling in the Treatment of Stroke 2/3 Trial
The purpose of this trial is to determine whether the combination of thrombolysis and hypothermia is superior to thrombolysis alone for the treatment of acute ischemic stroke.
- Trial name
- ICTuS2/3 (NCT01123161)
- Testing
- hypothermia and anti-shivering treatment, Group1: IV t-PA and normothermia
- Where
- 31 sites in United States, Austria and 1 more
- Volunteers
- 120 people
- Sponsor
- University of California, San Diego
Heart Attack, Stroke
CV Wizard: Does a Clinical Decision Support Tool Improve CVD Risk Factor Control in Safety Net Clinics?
This project aims to reduce disparities in cardiovascular disease (CVD) risk factor control and in rates of heart attacks and strokes among the low-income, racially / ethnically diverse Americans who receive primary care at…
- Conditions
- Heart Attack, Stroke, Cardiovascular Diseases
- Trial name
- CV_WIZARD (NCT03001713)
- Testing
- CV WIZARD
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Kaiser Permanente
Stroke, Cerebrovascular Accident
Non-invasive Brain Stimulation and Occupational Therapy To Enhance Stroke Recovery
The purpose of this study is to determine whether a non-painful, non-invasive, brain-stimulation technique called transcranial direct current stimulation (tDCS) combined with traditional physical-occupational therapy (OT) will…
- Conditions
- Stroke, Cerebrovascular Accident, CVA, Acute Stroke
- Trial name
- TDCS+OT (NCT00792428)
- Testing
- Real Transcranial Direct Current Stimulation
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Normobaric Oxygen, Cerebral Ischemia
The Efficacy of Normobaric Oxygen on Chronic Cerebral Ischemia
Chronic cerebral ischemia (CCI) is viewed as an alarming state induced by long-term reduction in cerebral perfusion, which is associated with neurological deficits and high risk of stroke occurrence or recurrence.
- Trial name
- NCT03745092
- Testing
- normobaric oxygen, room air
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Capital Medical University
Myocardial Infarction, Cardiovascular Death
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
This study is being carried out to see if a new drug called ticagrelor given twice daily in addition to the ASA therapy decreases the frequency of cardiovascular events (e.g., death from heart disease, heart attack, or stroke).
- Conditions
- Myocardial Infarction, Cardiovascular Death, Atherothrombosis, Stroke
- Trial name
- PEGASUS (NCT01225562)
- Testing
- Ticagrelor 90 mg, Ticagrelor 60 mg
- Where
- 826 sites in United States, Argentina and 29 more
- Volunteers
- 21,379 people
- Sponsor
- AstraZeneca
Stroke, Brain Infarction
Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke (CLEAR-FDR)
The primary goal of this trial is to determine if individuals with acute ischemic stroke treated with a full dose of IV recombinant tissue plasminogen activator (rt-PA) plus IV eptifibatide started within 3 hours of symptom onset…
- Trial name
- CLEAR-FDR (NCT01977456)
- Testing
- Eptifibatide
- Where
- 8 sites in United States
- Volunteers
- 27 people
- Sponsor
- Arthur Pancioli
Stroke, Ischemia
Analysis of Revascularization in Ischemic Stroke With EmboTrap
The study objective is to examine the recanalization efficacy of the EmboTrap device and its associated performance characteristics and to record associated clinical outcomes in a manner that facilitates relevant comparison of…
- Trial name
- ARISEII (NCT02488915)
- Testing
- EmboTrap® Revascularization Device
- Where
- 12 sites in United States, Belgium and 2 more
- Volunteers
- 228 people
- Sponsor
- Neuravi Inc.
Atherosclerosis, Ischemia
Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737)
The study is designed to determine whether vorapaxar, when added to the existing standard of care (SOC) for preventing heart attack and stroke (eg, aspirin, clopidogrel) in participants with a known history of atherosclerosis…
- Conditions
- Atherosclerosis, Ischemia, Myocardial Infarction, Cerebrovascular Accident
- Trial name
- NCT00526474
- Testing
- Vorapaxar
- Volunteers
- 26,449 people
- Sponsor
- Merck Sharp & Dohme LLC
Ischemic Stroke
Percutaneous Recanalization in Ischemic Stroke Management (PRIISM): A Feasibility Clinical Study
The primary study objective is to assess the feasibility of using the MindFrame System to safely and effectively restore blood flow in a thrombotic neurovascular occlusion in patients experiencing an ischemic stroke.
- Trial name
- PRIISM (NCT00810095)
- Testing
- MindFrame System
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- MindFrame, Inc.
Leukodystrophy, White Matter Disease
LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
Leukodystrophies, and other heritable disorders of the white matter of the brain, were previously resistant to genetic characterization, largely due to the extreme genetic heterogeneity of molecular causes.
- Conditions
- Leukodystrophy, White Matter Disease, 4H Syndrome, Adrenoleukodystrophy
- Trial name
- NCT02699190
- Where
- United States
- Volunteers
- 236 people
- Sponsor
- Children's Hospital of Philadelphia